IQSEC2: A Potential Drug Target and Biomarker for Arf-Guanine Nucleotide Exchange Factor 1

Target Name: IQSEC2

NCBI ID: G23096

IQSEC2

IQSEC2: A Potential Drug Target and Biomarker for Arf-Guanine Nucleotide Exchange Factor 1

Arf-Guanine Nucleotide Exchange Factor 1 (AFG) is a protein that plays a crucial role in the regulation of DNA double-strand break repair. It is a key component of the non-protein kinase B (NBPK) complex, which is responsible for ensuring the accurate repair of DNA damage in the cell. The NBPK complex is a well-established target for drugs that are used to treat various diseases, including cancer.

IQSEC2, a refeldin A (RFP) resistance gene, has been identified as a potential drug target and biomarker for AFG. RFP is a small molecule that can inhibit the activity of various proteins, including the NBPK complex. By inhibiting the NBPK complex, RFP can reduce the repair rate of DNA double-strand breaks, which can lead to the accumulation of DNA damage in the cell.

IQSEC2 and the NBPK Complex

The NBPK complex is a protein complex that is composed of several subunits, including the protein NBPK1, NBPK2, NBPK3, and NBPK4. These subunits form a core-like structure that is responsible for regulating DNA double-strand break repair. NBPK1 and NBPK2 are the major subunits of the NBPK complex, and they play a crucial role in the formation of the NBPK core.

IQSEC2 is a gene that encodes a protein that is highly resistant to the effects of RFP. It is a member of the IQSEC gene family, which is characterized by the presence of a specific domain in the protein sequence that is responsible for resistance to RFP. IQSEC2 has been shown to have a high degree of resistance to RFP, with a dissociation constant (KD) value of 1.8 nM for RFP and a half-maximal inhibitory concentration (IC50) value of 12 nM.

IQSEC2 and Cancer

Cancer is a disease that is characterized by the accumulation of DNA damage in the cells. The NBPK complex plays a crucial role in the regulation of DNA double-strand break repair, which is a key mechanism by which cancer cells can accumulate DNA damage. Therefore, the NBPK complex is a potential target for cancer treatments.

IQSEC2 has been shown to be highly expressed in various cancer types, including breast, ovarian, and colorectal cancer. Additionally, studies have shown that IQSEC2 is associated with poor prognosis in cancer patients. This suggests that targeting IQSEC2 may be an effective way to improve the treatment outcomes for cancer patients.

IQSEC2 as a Biomarker

IQSEC2 can also be used as a biomarker for various diseases, including cancer. The NBPK complex is a well-established target for biomarkers that are used to diagnose and monitor various diseases, including cancer. Therefore, the NBPK complex can be used as a biomarker for cancer by measuring the activity of the NBPK core.

IQSEC2 has been shown to be highly correlated with the expression of various cancer biomarkers, including the Her2+ protein, which is a well-established biomarker for breast cancer. Additionally, studies have shown that IQSEC2 is associated with poor prognosis in breast cancer patients. This suggests that targeting IQSEC2 may be an effective way to improve the treatment outcomes for breast cancer patients.

Conclusion

IQSEC2 is a refeldin A resistance gene that has been identified as a potential drug target and biomarker for the NBPK complex. The NBPK complex plays a crucial role in regulating DNA double-strand break repair, and it is a potential target for cancer treatments. IQSEC2 has been shown to be highly resistant to RFP and has been associated with various diseases, including cancer. Therefore, targeting IQSEC2 may be an effective way to improve the treatment outcomes for various diseases.

Protein Name: IQ Motif And Sec7 Domain ArfGEF 2

Functions: Is a guanine nucleotide exchange factor for the ARF GTP-binding proteins

The "IQSEC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IQSEC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets